These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 28530383)

  • 21. Assessment of the Siksika chronic disease nephropathy-prevention clinic.
    Ward DR; Novak E; Scott-Douglas N; Brar S; White M; Hemmelgarn BR
    Can Fam Physician; 2013 Jan; 59(1):e19-25. PubMed ID: 23341675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complications of diabetes mellitus in childhood.
    Glastras SJ; Mohsin F; Donaghue KC
    Pediatr Clin North Am; 2005 Dec; 52(6):1735-53. PubMed ID: 16301091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Updated management for patients with cardiovascular disease and diabetes.
    Dugan J; Butts A; Collins BSJ; Saini PS; Bradley S
    JAAPA; 2019 Aug; 32(8):51-53. PubMed ID: 31348103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Solvay addresses unmet needs in the management of hypertensive patients with cardiometabolic and lipid disorders.
    Cardiovasc J Afr; 2009; 20(1):73-4. PubMed ID: 19287821
    [No Abstract]   [Full Text] [Related]  

  • 26. Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study).
    Erdine S; Ro YM; Tse HF; Howes LG; Aguilar-Salinas CA; Chaves H; Guindy R; Chopra P; Moller RA; Schou IM;
    J Hum Hypertens; 2009 Mar; 23(3):196-210. PubMed ID: 18800143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting cardiovascular risk in patients with diabetes: management of dyslipidemia.
    Ali YS; Linton MF; Fazio S
    Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):142-6. PubMed ID: 18316949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy.
    Athyros VG; Mitsiou EK; Tziomalos K; Karagiannis A; Mikhailidis DP
    Expert Opin Pharmacother; 2010 Apr; 11(5):723-30. PubMed ID: 20210681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Statins in hypertension: are they a new class of antihypertensive agents?
    Feldstein CA
    Am J Ther; 2010; 17(3):255-62. PubMed ID: 19918164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reducing complications in type 2 diabetes.
    Poirier SJ
    Am Fam Physician; 1998 Mar; 57(6):1238-9. PubMed ID: 9531907
    [No Abstract]   [Full Text] [Related]  

  • 31. Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant.
    Ahmed MH; Khalil AA
    Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1021-9. PubMed ID: 21060168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can Antihypertensive Treatment Restore the Risk of Cardiovascular Disease to Ideal Levels?: The Coronary Artery Risk Development in Young Adults (CARDIA) Study and the Multi-Ethnic Study of Atherosclerosis (MESA).
    Liu K; Colangelo LA; Daviglus ML; Goff DC; Pletcher M; Schreiner PJ; Sibley CT; Burke GL; Post WS; Michos ED; Lloyd-Jones DM
    J Am Heart Assoc; 2015 Sep; 4(9):e002275. PubMed ID: 26391135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Effect of Metabolic Surgery on the Complications of Diabetes: What Are the Unanswered Questions?
    Neff KJ; Le Roux CW
    Front Endocrinol (Lausanne); 2020; 11():304. PubMed ID: 32547487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
    Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
    Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Therapeutic approach to dyslipidemia and goal achievement in a Spanish population with type 2 diabetes without cardiovascular disease].
    Pérez A; González Blanco C; Hernández-Presa MÁ; Chaves J
    Endocrinol Nutr; 2011; 58(6):283-90. PubMed ID: 21641286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between Prescription and Control Status of Dyslipidemia and Hypertension among Japanese Patients with Diabetes.
    Sakamoto M; Edo N; Takahashi S; Okamura E; Uno K; Morita K; Ishikawa T; Asahi K; Iseki K; Moriyama T; Yamagata K; Tsuruya K; Fujimoto S; Narita I; Konta T; Kondo M; Kimura K; Ohashi Y; Watanabe T; Tsukamoto K
    J Atheroscler Thromb; 2019 Sep; 26(9):805-820. PubMed ID: 30726791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. REVIEW: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia.
    Ginsberg HN
    J Clin Endocrinol Metab; 2006 Feb; 91(2):383-92. PubMed ID: 16291700
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tannins and vascular complications of Diabetes: An update.
    Laddha AP; Kulkarni YA
    Phytomedicine; 2019 Mar; 56():229-245. PubMed ID: 30668344
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiac risk factors: new cholesterol and blood pressure management guidelines.
    Anthony D; George P; Eaton CB
    FP Essent; 2014 Jun; 421():28-43. PubMed ID: 24936717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Early and concurrent therapy of dyslipidemia and hypertension: when to start it and how to maintain patient´s good and long-term adherence?].
    Soška V
    Vnitr Lek; 2021; 67(1):37-40. PubMed ID: 33752389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.